These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21641335)

  • 1. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
    Fu Y; Huang R; Zheng Y; Zhang Z; Liang A
    Biochem Biophys Res Commun; 2011 Jul; 410(2):218-23. PubMed ID: 21641335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
    Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
    Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
    Weller M; Wick W; von Deimling A
    Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
    Zhu J; Zuo J; Xu Q; Wang X; Wang Z; Zhou D
    Med Hypotheses; 2011 Apr; 76(4):602-3. PubMed ID: 21284999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
    Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A
    Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β.
    Fu Y; Zheng Y; Chan KG; Liang A; Hu F
    Mol Biol Rep; 2014 Jun; 41(6):3907-13. PubMed ID: 24549719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 and IDH2 mutations in gliomas.
    Ducray F; Marie Y; Sanson M
    N Engl J Med; 2009 May; 360(21):2248-9; author reply 2249. PubMed ID: 19469031
    [No Abstract]   [Full Text] [Related]  

  • 12. Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
    Fu Y; Zheng Y; Li K; Huang R; Zheng S; An N; Liang A
    Biotechnol Lett; 2012 Mar; 34(3):441-6. PubMed ID: 22105553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 mutations in gliomas: when an enzyme loses its grip.
    Frezza C; Tennant DA; Gottlieb E
    Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of isocitrate dehydrogenase in glioma.
    Alexander BM; Mehta MP
    Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
    Lopez GY; Reitman ZJ; Solomon D; Waldman T; Bigner DD; McLendon RE; Rosenberg SA; Samuels Y; Yan H
    Biochem Biophys Res Commun; 2010 Jul; 398(3):585-7. PubMed ID: 20603105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.